Halberd's Quick Ratio

HALB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

Regardless of the sequential decrease in Current Liabilities, during the third quarter 2022, Quick Ratio deteriorated to 0.02 a new company low.

Within Medical Laboratories industry 56 other companies have achieved higher Quick Ratio than Halberd in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from to 6109.

Explain Quick Ratio?
How much Cash & cash equivalents HALB�s has?
What are HALB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

HALB Quick Ratio	(Apr 30 2022) Q3	(Jul 31 2021) Q3
Y / Y Current Liabilities Change	-	-	-	-	-
Y / Y Cash & cash equivalent Change	-	-	-	-	-
Quick Ratio MRQ	0.02	0.03	-	-	-
HALB's Total Ranking	# 6109	#	#	#	#
Seq. Current Liabilities Change	-61.2 %	-	-	-	-
Seq. Cash & cash equivalent Change	-79.75 %	-	-	-	-

Quick Ratio third quarter 2022 Company Ranking
Within:	No.
Medical Laboratories Industry	# 57
Healthcare Sector	# 1291
Overall Market	# 6109

Quick Ratio Statistics
High	Average	Low
0.03	0.02	0.02
(Jul 31 2021)		(Apr 30 2022)

Financial Statements
Halberd's Current Liabilities	$ 0 Millions	Visit HALB's Balance sheet
Halberd's Cash & cash equivalent	$ 0 Millions	Visit HALB's Balance sheet
Source of HALB's Sales		Visit HALB's Sales by Geography

Cumulative Halberd's Quick Ratio

HALB's Quick Ratio for the trailling 12 Months

HALB Quick Ratio	(Apr 30 2022) 12 Months	(Jul 31 2021) 12 Months	12 Months	12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	-	-	-	-	-
Quick Ratio TTM	0.03	0.03	-	-	-
Total Ranking TTM	#	#
Seq. Current Liabilities TTM Growth	38.8 %	-	-	-	-
Seq. Cash & cash equivalent TTM Growth	20.25 %	-	-	-	-

Quick ratio ranking by company, industry and sector >> Back to HALB Financial Strength Comparisons >> Go to Compare HALB Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the drop in Current Liabilities in the Q3 2022 to $0.48 millions, cumulative Quick Ratio remained unchanged at 0.03 above the HALB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 56 other companies have achieved higher Quick Ratio than Halberd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2021 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents HALB�s has?
What are HALB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 57
Healthcare Sector	# 1291
Within the Market	# 6109

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.03	0.02	0.02
(Jul 31 2021)		(Apr 30 2022)

Companies with similar Quick Ratio in the quarter ending Apr 30 2022, within Medical Laboratories Industry	Quick Ratio	Apr 30 2022 MRQ Cash & cash equivalent	Apr 30 2022 MRQ Current Liabilities
Fresh2 Group Ltd	0.04	$ 0.271 Millions	$ 6.128 Millions
Halberd Corporation	0.02	$ 0.008 Millions	$ 0.485 Millions
Aclarion Inc	0.01	$ 0.050 Millions	$ 6.738 Millions

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.